News & Updates

Show Multimedia Only

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

20 Jun 2023 by

In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.

20 Jun 2023

Visceral adipose tissue buildup tied to lower muscle density

20 Jun 2023

Age-related accumulation of visceral adipose tissue (VAT) in both men and women may result in lower paraspinal muscle density, suggests a study.

20 Jun 2023

AI predicts early-stage rheumatoid arthritis using MRI scans

20 Jun 2023 by

It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.

20 Jun 2023

Which factors contribute to skin neoplasms in Lynch syndrome patients?

20 Jun 2023

Individuals with Lynch syndrome (LS) often develop skin neoplasms, reports a recent study, which has identified several clinical factors that contribute to LS- and non-LS-related skin neoplasms.

20 Jun 2023

Add-on mRNA cancer vaccine delivers promise for melanoma

20 Jun 2023 by

Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.

20 Jun 2023

Mifepristone shows therapeutic promise in adenomyosis

20 Jun 2023

Use of mifepristone in the treatment of patients with adenomyosis appears to be safe and efficacious, reducing pain and inducing dysmenorrhea remission, as reported in a study.

20 Jun 2023

Abatacept halts RA progression early in high-risk group

20 Jun 2023 by

Treatment with abatacept for a year halts disease progression in high-risk patients presenting with signs of imminent onset of rheumatoid arthritis (RA) in the phase IIb APIPPRA trial.

20 Jun 2023

Dual-target oral drug outperforms tofacitinib in RA treatment

19 Jun 2023 by

The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.

19 Jun 2023

New-onset vs long-standing diabetes tied to higher pancreatic cancer risk

19 Jun 2023

People with diabetes mellitus (DM) have a higher risk of pancreatic cancer than those without DM, reveals a recent study. Among diabetic individuals, those with new-onset DM show a greater pancreatic cancer risk than those with long-standing DM.

19 Jun 2023

Secukinumab on par with adalimumab biosimilar in r-axSpA

19 Jun 2023 by

Treatment with secukinumab (SEC) shows no significant difference with adalimumab biosimilar (SDZ-ADL) in spinal radiographic progression, which remains low over 2 years, among patients with radiographic axial spondyloarthritis (r-axSpA), according to a phase IIIb study presented at EULAR 2023.

19 Jun 2023

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

Visceral adipose tissue buildup tied to lower muscle density

AI predicts early-stage rheumatoid arthritis using MRI scans

Which factors contribute to skin neoplasms in Lynch syndrome patients?

Add-on mRNA cancer vaccine delivers promise for melanoma

Mifepristone shows therapeutic promise in adenomyosis

Abatacept halts RA progression early in high-risk group

Dual-target oral drug outperforms tofacitinib in RA treatment

New-onset vs long-standing diabetes tied to higher pancreatic cancer risk

Secukinumab on par with adalimumab biosimilar in r-axSpA